Oramed’s oral insulin capsule, (ORMD-0801), was well tolerated by patients and no serious adverse events were observed. The insulin absorption was not affected when given before meal ingestion. Oramed the developer reported positive results from a Phase 2A study of its oral insulin capsule, ORMD-0801, on Type 1 diabetic patients. The completion of this study marks Oramed’s first clinical trial on patients with Type 1 Diabetes Mellitus, whereas, all Oramed’s trials up to date have been conducted on Type 2 diabetic patients. This study evaluated safety, tolerability, and food effects in Type 1 diabetic patients.
Currently, Oramed is conducting its Phase 2B clinical trial in South Africa, in which the company is evaluating the effects of ORMD-0801 on Type 2 diabetic patients.
For more information, please visit http://www.oramed.com.